XML 60 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Marketable Securities
9 Months Ended
Sep. 30, 2012
Available-for-sale Securities [Abstract]  
Marketable Securities
6. Marketable Securities
Rambus invests its excess cash and cash equivalents primarily in U.S. government sponsored obligations, commercial paper, corporate notes and bonds, money market funds and municipal notes and bonds that mature within three years.  As of September 30, 2012 and December 31, 2011, all of the Company’s cash equivalents and marketable securities had a remaining maturity of less than one year.
All cash equivalents and marketable securities are classified as available-for-sale. Total cash, cash equivalents and marketable securities are summarized as follows:
 
 
As of September 30, 2012
(Dollars in thousands)
 
Fair Value
 
Amortized
 Cost
 
Gross
 Unrealized
 Gains
 
Gross
 Unrealized
 Losses
 
Weighted
 Rate of
 Return
Money market funds
 
$
118,508

 
$
118,508

 
$

 
$

 
0.01
%
Corporate notes, bonds and commercial paper
 
56,886

 
56,906

 

 
(20
)
 
0.21
%
Total cash equivalents and marketable securities
 
175,394

 
175,414

 

 
(20
)
 
 

Cash
 
31,692

 
31,692

 

 

 
 

Total cash, cash equivalents and marketable securities
 
$
207,086

 
$
207,106

 
$

 
$
(20
)
 
 

 
 
As of December 31, 2011
(Dollars in thousands)
 
Fair Value
 
Amortized
 Cost
 
Gross
 Unrealized
 Gains
 
Gross
 Unrealized
 Losses
 
Weighted
 Rate of
 Return
Money market funds
 
$
127,559

 
$
127,559

 
$

 
$

 
0.01
%
Corporate notes, bonds and commercial paper
 
137,108

 
137,208

 

 
(100
)
 
0.29
%
Total cash equivalents and marketable securities
 
264,667

 
264,767

 

 
(100
)
 
 

Cash
 
24,789

 
24,789

 

 

 
 

Total cash, cash equivalents and marketable securities
 
$
289,456

 
$
289,556

 
$

 
$
(100
)
 
 



Available-for-sale securities are reported at fair value on the balance sheets and classified as follows:
 
September 30,
2012
 
December 31,
2011
 
(Dollars in thousands)
Cash equivalents
$
120,514

 
$
137,455

Short term marketable securities
54,880

 
127,212

Total cash equivalents and marketable securities
175,394

 
264,667

Cash
31,692

 
24,789

Total cash, cash equivalents and marketable securities
$
207,086

 
$
289,456



The Company continues to invest in highly rated, highly liquid debt securities. The Company holds all of its marketable securities as available-for-sale, marks them to market and regularly reviews its portfolio to ensure adherence to its investment policy and to monitor individual investments for risk analysis, proper valuation and unrealized losses that may be other than temporary.
The estimated fair value of cash equivalents and marketable securities classified by the length of time that the securities have been in a continuous unrealized loss position at September 30, 2012 and December 31, 2011 are as follows:
 
Fair Value
 
Gross Unrealized Loss
 
September 30,
2012
 
December 31,
2011
 
September 30,
2012
 
December 31,
2011
 
(In thousands)
Less than one year
 

 
 

 
 

 
 

Corporate notes, bonds and commercial paper
$
46,384

 
$
137,107

 
$
(20
)
 
$
(100
)


The unrealized loss at September 30, 2012 was insignificant in relation to the Company’s total available-for-sale portfolio. The unrealized loss can be primarily attributed to a combination of market conditions as well as the demand for and duration of the corporate notes and bonds. The Company has no intent to sell, there is no requirement to sell and the Company believes that it can recover the amortized cost of these investments. The Company has found no evidence of impairment due to credit losses in its portfolio. Therefore, these unrealized losses were recorded in other comprehensive income (loss). However, the Company cannot provide any assurance that its portfolio of cash, cash equivalents and marketable securities will not be impacted by adverse conditions in the financial markets, which may require the Company in the future to record an impairment charge for credit losses which could adversely impact its financial results.
See Note 14, “Fair Value of Financial Instruments,” for discussion regarding the fair value of the Company’s cash equivalents and marketable securities.